Backed with $180M-plus in cash, I/O trailblazer Lieping Chen spotlights NextCure's preclinical work on next-gen antibody
Right on the heels of nailing a $40 million upfront for its oncology R&D collaboration deal with Eli Lilly and bringing its tally of cash raised to $180 million with an ambitious venture round, Yale spinout NextCure has laid the scientific foundation for the immuno-oncology company in a new preclinical study just published in Nature Medicine.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
